DKFMA-102 is under clinical development by Dongkook Pharmaceutical and currently in Phase III for Prostate Cancer. According to GlobalData, Phase III drugs for Prostate Cancer have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how DKFMA-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DKFMA-102 overview
Leuprolide acetate (DKF-MA102) is under development for the treatment of prostate cancer. The drug candidate acts by targeting gonadotropin-releasing hormone receptor (GNRHR).
Dongkook Pharmaceutical overview
Dongkook Pharmaceutical (Dongkook) develops, manufactures and distributes pharmaceutical products. The company’s products include prescription drugs, nonprescription drugs, generic drugs, quasi-drugs, medical devices, active pharmaceutical ingredients and cosmetics. It’s pipeline products include DKF-310, DKM-413, DKM-412, DKF-313, DKF-340, DKF-361, DKF-363, DKF-325, DKF-334, DKF-335 and DKM-420. The company’s pipeline treats obesity, diabetes, dementia, osteoarthritis, benign prostatic hyperplasia, hypertension and respiratory inflammation. It provides products under the brand names Insadol Plus, Madecassol, Feramine Q, Sencia, Pansidil, Chisen, Karitopoten and Oramedi, among others. Dongkook is headquartered in Gangnam-gu, Seoul, South Korea.
For a complete picture of DKFMA-102’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
